Causaly today announced new scientific AI agents that provide research teams with the industry's most comprehensive ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus. A clinical trial ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The PGIM Jennison Focused Growth Fund rose 5.7%, slightly underperforming the Russell 1000 Growth Index. Click here to read ...